Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
ISMP Report Questions Nuplazid Safety, FDA Approval And Lack Of Warnings March 29, 2019 Irvin Jackson Add Your Comments It appears that federal regulators may have made a mistake when they determined that the antipsychotic drug Nuplazid was safe, according to the findings of a new report by a consumer advocacy group. The Institute for Safe Medication Practices (ISMP) released its QuarterWatch Report (subscription required) this week, looking at FDA adverse events for the second quarter of 2018, including hundreds of reports involving problems with Nuplazid. Researchers indicate that they “respectfully disagree” with the FDA’s decision to issue a statement in September 2018, which provided safety reassurances about the potential side effects of Nuplazid, indiating that the reassurances were not warranted by the data. Learn More About Nuplazid Lawsuits Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Nuplazid Lawsuits Learn More SEE IF YOU QUALIFY FOR COMPENSATION Nuplazid (pimavanserin) is an atypical antipsychotic, which is used to reduce hallucinations experienced by Parkinson’s disease patients. The drug was just introduced by Acadia Pharmaceuticals in April 2016, after it was approved by the FDA through a fast track “Breakthrough Therapy” process. However, an alarming number of Nuplazid problems have been reported by individuals nationwide. Last year, the FDA reported that its Adverse Events Reporting System (FAERS) had received 5,735 incidents involving problems with Nuplazid since 2016. Nuplazid side effects have also been linked to at least 712 death reports. While the reports do not necessarily mean that Nuplazid was the cause of the deaths, at least 500 of those fatality reports listed Nuplazid as the only suspect medication the patient was taking. In response to growing concerns, the FDA issued an updated safety communication in September, indicating that its review found no new or unexpected Nuplazid risks. “In assessing the reports of deaths, FDA considered that patients with Parkinson’s disease psychosis, for whom Nuplazid is indicated, have a higher mortality (death) rate due to their older age, advanced Parkinson’s disease, and other medical conditions,” the reviewers concluded. “Moreover, Nuplazid is primarily distributed through a patient support program and a specialty pharmacy network, which increases the likelihood that deaths will be reported to the manufacturer.” ISMP researchers raise seriuos questions about the FDA’s reassurances, indicating that their own review of the FDA’s data found 893 death reports, almost all submitted by the manufacturer. “But agency safety reviewers said most case reports had so little detail that they could not determine whether or not primavanserin contributed to the patient death,” ISMP researchers note. “On one hand, the patients were already at high risk of death from the underlying advanced Parkinson’s disease, but on the other, reviewers could not tell how many deaths had never been reported.” The ISMP report also notes that after just two months of use, 45% of Nuplazid users had either died or discontinued using the drug. They also found that a recent large clinical trial showed no benefit to Alzheimer’s patients after 12 weeks, suggesting that the drug carries few actual benefits. Researchers also questioned the clarity of the existing boxed warning on the drug, and noted that the number of reported deaths now exceeds 1,300, with nearly 40% of those giving no details. Since the drug was approved the for the treatment of hallucinations and delusions linked to Parkinson’s disease psychosis (PDP), Nuplazid generated about $125 million in sales last year for Acadia Pharmaceuticals. The ISMP first issued a warning about Nuplazid safety signals in its November 2017 QuarterWatch report, indicating that the FDA had received 2,236 adverse event reports over the course of its first year on the market, including 244 deaths and signs that the drug may actually worsen hallucinations in some cases. Potential side effects of Nuplazid reported to federal health regulators also include falls, insomnia, nausea, and fatigue. Tags: Acadia, Atypical Antipsychotic, Congress, Drug Side Effects, Hallucinations, Nuplazid, Parkinsons Disease Image Credit: | More Nuplazid Lawsuit Stories FDA Rejects Nuplazid Application for Treatment of Alzheimer’s Disease Psychosis August 8, 2022 Nuplazid Safety Risks May Lead FDA To Re-Review New Medication, Gottlieb Tells Senate April 26, 2018 Nuplazid Problems Linked To Hundreds Of Patient Deaths: Report April 11, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermCommentsThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Link Between Hair Relaxers and Cancer To Be Examined by Court During “Science Day” (Posted: 3 days ago) A federal judge has called for Science Day presentations to explain to the court the theories and evidence linking hair relaxer to increased cancer risks. MORE ABOUT: HAIR RELAXER LAWSUITHair Relaxer Cancer Lawsuits Continue To Be Filed as Lawyers Prepare First Cases for Trial (06/24/2025)Replacement Hair Relaxer Lawsuit To Be Selected for MDL Bellwether Pool (06/12/2025)Hair Relaxer Lawsuits and Talcum Powder Lawsuits Designated as New Mass Torts in Philadelphia (05/30/2025) Lawyers Ordered To Engage in Talcum Powder Settlement Talks in MDL (Posted: 3 days ago) A special mediator has been appointed to oversee negotiations between Johnson & Johnson and tens of thousands of women who say its talcum powder products caused them to develop reproductive system cancers. MORE ABOUT: TALCUM POWDER LAWSUITSTalcum Powder Ovarian Cancer Lawsuit Selected for First Federal Bellwether Trial (07/01/2025)Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions (06/20/2025)Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA (05/22/2025) Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: 4 days ago) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)
Link Between Hair Relaxers and Cancer To Be Examined by Court During “Science Day” (Posted: 3 days ago) A federal judge has called for Science Day presentations to explain to the court the theories and evidence linking hair relaxer to increased cancer risks. MORE ABOUT: HAIR RELAXER LAWSUITHair Relaxer Cancer Lawsuits Continue To Be Filed as Lawyers Prepare First Cases for Trial (06/24/2025)Replacement Hair Relaxer Lawsuit To Be Selected for MDL Bellwether Pool (06/12/2025)Hair Relaxer Lawsuits and Talcum Powder Lawsuits Designated as New Mass Torts in Philadelphia (05/30/2025)
Lawyers Ordered To Engage in Talcum Powder Settlement Talks in MDL (Posted: 3 days ago) A special mediator has been appointed to oversee negotiations between Johnson & Johnson and tens of thousands of women who say its talcum powder products caused them to develop reproductive system cancers. MORE ABOUT: TALCUM POWDER LAWSUITSTalcum Powder Ovarian Cancer Lawsuit Selected for First Federal Bellwether Trial (07/01/2025)Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions (06/20/2025)Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA (05/22/2025)
Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: 4 days ago) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)